Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

Summary

Video-assisted thoracic surgery (VATS) has been recommended by clinical guidelines as one of the preferred surgeries for early-stage non-small cell lung cancer (NSCLC) for many years. However, VATS has inherent drawbacks, so at the beginning of this century, robotic-assisted thoracoscopic surgery (RATS) was first applied for lung resection. In recent years, RATS has developed rapidly, but there are still many unsolved scientific problems in the field of RATS. Thus, a multicenter prospective randomized controlled trial was conducted with stage I-II NSCLC patients as the study subject and 5-year DFS as the primary endpoint to compare the short-term and long-term outcomes of RATS and VATS in the treatment of early-stage NSCLC.

Conditions

• Non Small Cell Lung Cancer

Interventions

PROCEDURE

Robot-assisted lobectomy

Patients will receive robot-assisted lobectomy using Da Vinci surgical system

PROCEDURE

Video-assisted lobectomy

Patients will receive video-assisted lobectomy

Sponsors & Collaborators

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  collaborator OTHER

• The General Hospital of Eastern Theater Command

  collaborator OTHER

• Gansu Provincial Hospital

  collaborator OTHER

• Tang-Du Hospital

  collaborator OTHER

• Wuhan TongJi Hospital

  collaborator OTHER

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Shenzhen People's Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Jiangxi Provincial People's Hopital

  collaborator OTHER

• Sichuan Cancer Hospital and Research Institute

  collaborator OTHER

• Lanzhou University Second Hospital

  collaborator OTHER

• Shenzhen Third People's Hospital

  collaborator OTHER

• Qianfoshan Hospital

  collaborator OTHER

• Guangxi Nanxishan Hospital

  collaborator UNKNOWN

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Hao-Xian Yang, M.D. · Sun Yat-sen University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-08-25

Primary Completion

2030-12-31

Completion

2030-12-31

Countries

• China

Study Locations